

## Synthesis, Characterization and Antimicrobial Activity of Novel Chalcones Analogues

BUSHRA AHMED KATEB<sup>1,2</sup>, ABDULKAREEM ALI HUSSIAN<sup>1,2</sup>,  
P. A. KULKARNI<sup>1</sup>, M. A. BASEER<sup>1</sup>

<sup>1</sup>P. G. Research Center, Department of Chemistry, Yeshwant Mahavidyalaya,  
Nanded-431602 (MS), India

<sup>2</sup>Hodiedah University, Education College, Yemen  
*nice1422@gmail.com*

Received 14 January 2016 / Accepted 13 February 2016

**Abstract:** A new series of chalcones (**3a-j**) have been prepared by Claisen-Schmidt condensation between substituted acetophenone and substituted aldehyde. All these compounds were characterized by physical and spectral methods such as melting point, IR, <sup>1</sup>H NMR and Mass analysis. All the synthesized compounds have been screened for their antimicrobial activity.


**Keywords:** Chalcones, Spectral analysis, Anti microbial Activity

### Introduction

Chalcones are a major class of natural products belonging to the flavonoid family. They are considered as the precursors of flavonoids and isoflavonoids. They are also the precursors of a number of biologically important heterocycles such as benzothiazepines, pyrazolines and flavones<sup>1</sup>.

Chalcones (trans-1, 3-diaryl-2propen-1-ones) are  $\alpha$ ,  $\beta$ -unsaturated ketones consisting of two aromatic rings having diverse array of substituents. Rings are interconnected by a highly electrophonic three carbon  $\alpha$ ,  $\beta$ -unsaturated carbonyl system that assumes linear or nearly planar structure<sup>2-4</sup>. They contain the electron ketoethylenic group ( $-\text{CO}-\text{CH}=\text{CH}-$ ). Chalcones possess conjugated double bonds and a completely delocalized  $\pi$ - system on both benzene rings. Chalcones have been used as intermediate for the preparation of compounds having therapeutic value<sup>5-7</sup>. Chalcones and their derivatives, whether synthetic or naturally occurring are an interesting and significant group of molecules as they possess a wide range of pharmacological activities such as anti-inflammatory, antimicrobial, antifungal, antibacterial, antioxidant, cytotoxic antitumor, anticancer, antimitotic, antileishmanial, antimalarial, antitubercular, antiviral and so on<sup>8-21</sup>.

The most convenient method is the Claisen Schimdt condensation of equimolar quantities of aryl methyl ketone with aryl aldehyde in the presence of alcoholic alkali<sup>22</sup>.



## Results and Discussion

A variety of novel chalcones were synthesized via Claisen-Schmidt condensation of substituted acetophenones and aromatic benzaldehyde (Table 1). The reaction proceeded at room temperature. Work up procedure is simple and yield of the product is excellent.

All the newly synthesized chalcones were characterized by their chemical, physical and spectral analysis data (Table 2) and are further subjected to antimicrobial studies which exhibit moderate to good activity.


**Table 2.** Physical data of synthesized chalcones

Compd. No.	Product	Mol. Formula	Yield %	M.P., °C	Solubility
1	<b>3a</b>	C <sub>13</sub> H <sub>7</sub> O <sub>2</sub> I <sub>2</sub> BrS	90	176-178	DMF
2	<b>3b</b>	C <sub>13</sub> H <sub>7</sub> O <sub>2</sub> I <sub>2</sub> BrS	92	162	DMF
3	<b>3c</b>	C <sub>13</sub> H <sub>7</sub> O <sub>2</sub> ClI <sub>2</sub> BrS	80	178	DMF
4	<b>3d</b>	C <sub>14</sub> H <sub>10</sub> O <sub>2</sub> I <sub>2</sub> BrS	92	142	DMF
5	<b>3e</b>	C <sub>17</sub> H <sub>14</sub> I <sub>2</sub> O <sub>4</sub>	86	162-164	DMF
6	<b>3f</b>	C <sub>17</sub> H <sub>14</sub> I <sub>2</sub> O <sub>4</sub>	88	174-176	DMF
7	<b>3g</b>	C <sub>17</sub> H <sub>14</sub> ClI <sub>2</sub> O <sub>4</sub>	80	178	DMF
8	<b>3h</b>	C <sub>18</sub> H <sub>17</sub> IO <sub>4</sub>	90	159	DMF
9	<b>3i</b>	C <sub>17</sub> H <sub>11</sub> Ni <sub>2</sub> O <sub>2</sub>	88	150	DMF
10	<b>3j</b>	C <sub>15</sub> H <sub>10</sub> BrClO <sub>3</sub>	85	108-110	DMF

### Spectral analysis of the compounds

The structure of the compounds were done by spectral analysis (IR, <sup>1</sup>H NMR, Mass) and the results are shown below

#### Compound 3a




(*E*)-3-(5-Bromothiophen-2-yl)-1-(4-hydroxy-3,5-diiodophenyl)prop-2-en-1-one

FTIR (KBr, cm<sup>-1</sup>): 3224(OH), 1646(C=O), 1576(C=C), 1465(C-C Aromatic str), 683(C-Br).  
<sup>1</sup>H NMR: 7.24(d, 1H, H<sub>3</sub>), 7.48(d, 1H, H<sub>4</sub>), 7.49(d, 1H, H<sub>α</sub>, J=15Hz), 7.58(d, 1H, H<sub>β</sub>, J=15Hz), 7.48(s, 1H, H<sub>5</sub>), 7.53(s, 1H, H<sub>6</sub>), 8.43(s, 1H, OH).

M.S. (*m/z*): (M)= 560(m), 561(m+1), 558(m-2).


#### Compound 3b



(*E*)-3-(5-Bromothiophen-2-yl)-1-(2-hydroxy-3,5-diiodophenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3425(OH), 1623(C=O), 1546(C=C), 1419(C-C Aromatic str), 621(C-Br).  $^1\text{H}$  NMR: 7.33(d, 1H,  $\text{H}_3$ ), 7.48(d, 1H,  $\text{H}_4$ ), 7.73(d, 1H,  $\text{H}_\alpha$ ,  $J=15\text{Hz}$ ), 7.97(d, 1H,  $\text{H}_\beta$ ,  $J=15\text{Hz}$ ), 8.27(s, 1H,  $\text{H}_5$ ), 8.55(s, 1H,  $\text{H}_6$ ), 13.7(s, 1H, OH). M.S. ( $m/z$ ): (M) = 558(m-2).


### Compound 3c



(*E*)-3-(5-Bromothiophen-2-yl)-1-(5-hydroxy-3-iodophenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3436(OH), 1635(C=O), 1526(C=C), 1419(C-C Aromatic str), 621(C-Br). 802(C-Cl), 675(C-Br).  $^1\text{H}$  NMR: 7.12(d, 1H,  $\text{H}_3$ ), 7.21(d, 1H,  $\text{H}_4$ ), 7.27(d, 1H,  $\text{H}_\alpha$ ,  $J=15\text{Hz}$ ), 7.97(d, 1H,  $\text{H}_\beta$ ,  $J=15\text{Hz}$ ), 8.23(s, 1H,  $\text{H}_5$ ), 8.47(s, 1H,  $\text{H}_6$ ), 13.46(s, 1H, OH). M.S. ( $m/z$ ): 468(m).


### Compound 3d



(*E*)-3-(5-Bromothiophen-2-yl)-1-(2-hydroxy-3-iodo-5-methylphenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3425(OH), 1639(C=O), 1569(C=C), 1415(C-C Aromatic str), 675(C-Br). 802(C-Cl), 675(C-Br).  $^1\text{H}$  NMR: 2.32(s, 3H,  $\text{CH}_3$ ), 7.27(d, 1H,  $\text{H}_3$ ), 7.52(d, 1H,  $\text{H}_4$ ), 7.65(d, 1H,  $\text{H}_\alpha$ ,  $J=15\text{Hz}$ ), 7.95(d, 1H,  $\text{H}_\beta$ ,  $J=15\text{Hz}$ ), 7.85(s, 1H,  $\text{H}_5$ ), 8.04(s, 1H,  $\text{H}_6$ ), 13.46(s, 1H, OH). M.S. ( $m/z$ ): 450(m+1), 448(m-1), 447(m-2).


### Compound 3e



(*E*)-3-(2,5-Dimethoxyphenyl)-1-(4-hydroxy-3,5-diiiodophenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3382(OH), 1658(C=O), 1589(C=C), 1492(C-C Aromatic str).  $^1\text{H}$ NMR: 3.81(s, 3H, OMe), 3.85(s, 3H, OMe), 7.00(s, 1H,  $\text{H}_3$ ), 7.01(d, 1H,  $\text{H}_3$ ), 7.57(d, 1H,  $\text{H}_4$ ), 7.78(d, 1H,  $\text{H}_\alpha$ ,  $J=15\text{Hz}$ ), 8.00(d, 1H,  $\text{H}_\beta$ ,  $J=15\text{Hz}$ ), 8.45-8.50(s, 2H,  $\text{H}_6$ ,  $\text{H}_7$ ), 10.28(s, 1H, OH). M.S. ( $m/z$ ): 536(m), 535(m-1), 534(m-2).


### Compound 3f



(*E*)-3-(2,5-Dimethoxyphenyl)-1-(2-hydroxy-3,5-diiiodophenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3433(OH), 1635(C=O), 1558(C=C), 1431(C-C Aromatic str).  $^1\text{H}$ NMR: 3.82(s,3H,OMe), 3.86(s,3H,OMe), 7.02(s,1H<sub>5</sub>)7.07(d,1H<sub>3</sub>)7.46(d,1H<sub>4</sub>)8.00(d, 1H, H $\alpha$ , J=15Hz), 8.22(d, 1H, H  $\beta$ ,J=15Hz), 8.23(s,1H,H<sub>6</sub>), 8.57(s,1H<sub>7</sub>), 13.84(s,1H, OH). M.S. ( $m/z$ ): 535(m-1), 534(m-2).


### Compound 3g



(*E*)-1-(5-chloro-3-iodophenyl)-3-(2,5-dimethoxyphenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3425(OH), 1667(C=O), 1550(C=C), 1496(C-C Aromatic str). 785(C-Cl).  $^1\text{H}$ NMR: 3.80(s,3H,OMe), 3.85(s,3H,OMe), 7.03(s,1H<sub>5</sub>)7.22(d,1H<sub>3</sub>)7.50(d,1H<sub>4</sub>)8.04(d, 1H, H $\alpha$ , J=15Hz), 8.12(d, 1H, H  $\beta$ ,J=15Hz), 8.16(s,1H,H<sub>6</sub>), 8.26(s,1H<sub>7</sub>), 13.51(s,1H, OH). M.S. ( $m/z$ ): 443(m-1), 445(m+1).


### Compound 3h



(*E*)-3-(2,5-dimethoxyphenyl)-1-(2-hydroxy-3-iodo-5-methylphenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 3440(OH), 1631(C=O), 1562(C=C), 1430(C-C Aromatic str).  $^1\text{H}$  NMR: 3.80(s,3H,OMe),3.85(s,3H,OMe), 7.03(s,1H<sub>5</sub>)7.22(d,1H<sub>3</sub>)7.50(d,1H<sub>4</sub>)8.04(d, 1H, H $\alpha$ , J=15Hz), 8.12(d, 1H, H  $\beta$ ,J=15Hz), 8.16(s,1H,H<sub>6</sub>), 8.26(s,1H<sub>7</sub>), 13.51(s,1H, OH). M.S. ( $m/z$ ): 423 (m-1).


### Compound 3i



(*E*)-1-(4-Hydroxy-3,5-diiodophenyl)-3-(1H-indol-3-yl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 1663(C=O), 1570(C=C), 1461(C-C Aromatic str).  $^1\text{H}$  NMR: 7.18((d, 1H, H $\alpha$ ,J=15Hz), 7.26(d, 1H, H  $\beta$ ,J=15Hz), 8.05(s,1H,H<sub>3</sub>), 8.12(s,1H,H<sub>4</sub>),8.14(s,1H,H<sub>5</sub>), 8-8.45(m,4H,Ar-H), 9.95(s,1H, OH), 11.99(s,1H,NH) .M.S. ( $m/z$ ): 423 (m-1).

### Compound 3j



(*E*)-1-(3-Bromo-5-chloro-2-hydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

FTIR (KBr,  $\text{cm}^{-1}$ ): 1641(C=O), 1563(C=C), 1422(C-C Aromatic str).  $^1\text{H}$  NMR: 7.40(d, 1H,  $\text{H}_\alpha$ ,  $J=15\text{Hz}$ ), 8.51(d, 1H,  $\text{H}_\beta$ ,  $J=15\text{Hz}$ ), 7.44-7.77(m, 4H, Ar-H), 9.95(s, 1H, OH), 7.61(s, 1H,  $\text{H}_3$ , Ar), 7.72(s, 1H,  $\text{H}_4$ ), 11.99(s, 1H, NH), 8.24(s, 1H, OH). M.S. ( $m/z$ ): 353 (M), 355( $m+2$ ), 351( $m-2$ ).

### Antimicrobial activity

Antimicrobial screening was done using disc diffusion method<sup>26</sup> at a concentration of 500  $\mu\text{g/mL}$ .

### Procedure

The test was performed according to the disk diffusion method<sup>26</sup> adopted with some modification for the prepared compound using Penciline and streptomycin as references. The prepared compounds were tested against one strain of Gram +ve bacteria, Gram -ve bacteria, fungi. Whatman filter paper disk of 5 mm diameter were sterilized by autoclaving for 15 min at 121  $^\circ\text{C}$ . The sterile disk were impregnated with different compounds (600 g/disk). Agar plates were surface inoculated uniformly from the both culture of the tested microorganism. The disk were placed on the medium suitably spaced apart on the plate were incubated at 50  $^\circ\text{C}$  for 1 h to permit good diffusion and then transferred to an incubator at 37  $^\circ\text{C}$  for 24 h for bacteria and 28  $^\circ\text{C}$  for 72 h for fungi.

The compounds were evaluated for antibacterial activity against *Staphylococcus aureus* gr +ve, *Escherichia coli* gr -ve *Bacillus subtilis* gr +ve, *Pseudomonas aeruginosa* gr -ve, and antifungal activity against *Aspergillus oryzae*, *Aspergillus niger*. DMSO was used as solvent control. The results of antimicrobial data are summarized in Table 3. All compounds show the moderate to good activity against bacteria, but for all compounds did not stop the growth of *Aspergillus oryzae* fungus and all compounds were not effective towards *Aspergillus niger* fungus.

**Table 3.** Antimicrobial activity of synthesized compounds

Compounds	Gram positive bacteria		Gram negative bacteria		Fungus	
	<i>Staph aureus</i>	<i>Bacillus subtilis</i>	<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>	<i>Aspergillus oryzae</i>	<i>Aspergillus niger</i>
<b>3a</b>	++	++	-ve	++	-ve	-
<b>3b</b>	-	-	-ve	-ve	-ve	-
<b>3c</b>	-	-	-ve	-ve	-ve	-
<b>3d</b>	-	-	-ve	-ve	-ve	-
<b>3e</b>	++	++	-ve	++	-ve	-
<b>3f</b>	-	-	-ve	-ve	-ve	-
<b>3g</b>	-	-	-ve	+	-ve	-
<b>3h</b>	-	-	-ve	-ve	-ve	-
<b>3i</b>	++	++	+	++	-ve	-
<b>3j</b>	++	+	-ve	+	-ve	-
Penciline 1	+	+	+	+	X	X
Streptomycin 2	++	++	++	++	X	X

++ = Clear Zone of Inhibition + = Minimum Zone of Inhibition -ve = Growth (Antibacteria and Antifungal Activities Observed) - = No Effect X = Not applicable, Standard 1 Penciline +, Standard 2 Streptomycin++

## Conclusion

We have reported some novel chalcones using substituted acetophenone with substituted aldehyde with high yield. The newly synthesized chalcones were confirmed by spectral analysis and further evaluated for their antimicrobial activity. The antibacterial activity revealed that of the compounds showed moderate to good activity against the pathogens used, the result was negative on fungus.

## Acknowledgement

The authors are thankful to Head of department of Chemistry, Head of department of Microbiology, Principal of Yeshwant College, Nanded for providing lab facilities for the research work.

## References

1. Rahman M A, *Chem Sci J.*, 2011, **29**, 1-16
2. Awasthi S K, Mishra N, Kumar B, Sharma M, Bhattacharya A, Mishra L C and Bhasin V K, *Med Chem Res.*, 2009, **18**(6), 407-420; DOI:10.1007/s00044-008-9137-9
3. Cheng M S, Shili R and Kenyon G, *Chinese Chem Lett.*, 2000, **11**(10), 851-854.
4. Lim S S, Kim H S and Lee D U, *Bulletin Korean Chem Soc.*, 2007, **28**(12), 2495-2497; DOI:10.5012/bkcs.2007.28.12.2495
5. Straub T S, *Tetrahedron Lett.*, 1995, **36**, 663-664; DOI:10.1016/0040-4039(94)02346-D
6. Sandler S and Karo W, In Organic Functional Group Preparations. 1972, **3**, 372; DOI:10.1016/b978-0-08-092558-5.50004-6
7. Bergman E D, Ginsibm L and Pappo R, *Org React.*, 1959, **10**, 179; DOI:10.1002/0471264180.or010.03
8. Bandgar B P, Patil S A, Gacche R N, Korbadi B L, Hote B S, Kinkar S N and Jalde S S, *Bioorg Med Chem Lett.*, 2010, **20**(2), 730-733; DOI:10.1016/j.bmcl.2009.11.068
9. Cabrera M, Simoens M, Falchi G, Lavaggi ML, Piro O E, Castellano E E, Vidal A, Azqueta A, Monge A, Cerain AL, Sagrera G, Seoane G, Cerecetto H and Gonzalez M, *Bioorg Med Chem.*, 2007, **15**(10), 3356-3367; DOI:10.1016/j.bmc.2007.03.031
10. Patel A A and Mehta A G, *J Saudi Chem Soc.*, 2010, **14**(2), 203-208; DOI:10.1016/j.jscs.2010.02.012
11. Suryawanshi S N, Chandra N, Kumar P, Porwal J and Gupta S, *Eur J Med Chem.*, 2008, **43**(11), 2473-2478; DOI:10.1016/j.ejmech.2007.12.014
12. Hayat F, Moseley E, Salahuddin A, Zyl R L V and Azam A, *Eur J Med Chem.*, 2011, **46**(5), 1897-1905; DOI:10.1016/j.ejmech.2011.02.004
13. Kumar N, Chauhan A and Drabu S, *Biomed Pharmacother.*, 2011, **65**(5), 375-380; DOI:10.1016/j.biopha.2011.04.023
14. Agarwal A, Srivastava K, Purib S K, Chauhan P M S, *Bioorg Med Chem.*, 2005, **13**(15), 4645-4650; DOI:10.1016/j.bmc.2005.04.061
15. Bandgar B P, Gawande S S, Bodade R G, Gawande N M and Khobragade C N, *Bioorg Med Chem.*, 2009, **17**(24), 8168-8173; DOI:10.1016/j.bmc.2009.10.035
16. Bandgar B P and Gawande S S, *Bioorg Med Chem.*, 2010, **18**(5), 2060-2065; DOI:10.1016/j.bmc.2009.12.077
17. Sharma A, Chakravarti B, Gupta M P, Siddiqui J A, Konwar R and Tripathi R P, *Bioorg Med Chem.*, 2010, **18**(13), 4711-4720; DOI:10.1016/j.bmc.2009.12.077

18. Insuasty B, Tigreros A, Orozco F, Quiroga J, Abonia R, Nogueras M, Sanchez A and Cobo J, *Bioorg Med Chem.*, 2010, **18(14)**, 4965-4974;  
[DOI:10.1016/j.bmc.2010.06.013](https://doi.org/10.1016/j.bmc.2010.06.013)
19. Liaras K, Geronikaki A, Glamoclija J, Ciric A and Sokovic M, *Bioorg Med Chem.*, 2011, **19(10)**, 3135-3140; [DOI:10.1016/j.bmc.2011.04.007](https://doi.org/10.1016/j.bmc.2011.04.007)
20. Liaras K, Geronikaki A, Glamoclija J, Ciric A and Sokovic M, *Bioorg Med Chem.*, 2011, **19(24)**, 7349-7356; [DOI:10.1016/j.bmc.2011.10.059](https://doi.org/10.1016/j.bmc.2011.10.059)
21. Anand N, Singh P, Sharma A, Tiwari S, Singh V, Singh D K, Srivastava K K and Singh B N, *Bioorg Med Chem.*, 2012, **20(17)**, 5150-5163;  
[DOI:10.1016/j.bmc.2012.07.009](https://doi.org/10.1016/j.bmc.2012.07.009)
22. Taylor E C and Morrison R W, *J Org Chem.*, 1967, **32(8)**, 2379-2382;  
[DOI:10.1021/jo01283a004](https://doi.org/10.1021/jo01283a004)
23. Padhy A K, Bardham M and Danda C S, *Indian J Chem.*, 2003, **42B(4)**, 910-915.
24. Nakum K H and Shah V H, *Indian J Het Chem.*, 2002, **12(1)**, 37.
25. Nagham M A J, *Chem Chemi Sci.*, 2013, **3(2)**, 70-78.
26. Afaf H, El-masry H H, Fahmy and Ali S H, Abdelwahed, *Molecules*, 2000, **5(12)**, 1429-1438; [DOI:10.3390/51201429](https://doi.org/10.3390/51201429)